Caxton Associates LP Gritstone Bio, Inc. Transaction History

Caxton Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.13 - $3.74 $68,901 - $120,981	-32,348 Reduced 26.93%	87,786 $244,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $54,128 - $97,780	24,944 Added 26.2%	120,134 $414,000
Q3 2022 Nov 14, 2022	BUY	$2.46 - $4.75 $234,167 - $452,152	95,190 New	95,190 $245,000
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $55,601 - $168,185	-13,797 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.76 - $13.71 $120,861 - $189,156	13,797 New	13,797 $177,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.